Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Scott D. Solomon et al.|New England Journal of Medicine|2019Cited by 6.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsSøren Lund Kristensen, John J.V. McMurray, Rasmus Rørth et al.|The Lancet Diabetes & Endocrinology|2019Cited by 1.6k
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathyKaren Sliwa, John J.V. McMurray, Denise Hilfiker‐Kleiner et al.|European Journal of Heart Failure|2010Cited by 1.1k
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of CardiologyPetar Seferović, John J.V. McMurray, Mark C. Petrie et al.|European Journal of Heart Failure|2018Cited by 716
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Subodh Verma, Marco A. Alcocer‐Gamba et al.|New England Journal of Medicine|2024Cited by 693